Abstract
Abstract
Background
We aimed to determine (1) the test–retest reliability of a newly developed portable fixed dynamometer (PFD) as compared to the hand-held dynamometer (HHD) in patients with motor neuron disease (MND) and (2) the PFD’s ability to reduce possible examiner-induced ceiling effects.
Methods
Test–retest reliability of isometric muscle strength of the quadriceps was measured in patients with MND and non-neurological controls using the HHD and PFD. Reliability was estimated by the intraclass correlation coefficient (ICC) and standard error of measurement (SEM) using linear mixed effects models, and the Bland–Altman method of agreement.
Results
In total, 45 patients with MND and 43 healthy controls were enrolled in this study. The ICC of the PFD was excellent and similar in both patients and controls (ICC Patients 99.5% vs. ICC Controls 98.6%) with a SEM of 6.2%. A strong examiner-induced ceiling effect in HHD was found when the participant’s strength exceeded that of examiner. Employing the PFD increased the range of muscle strength measurements across individuals nearly twofold from 414 to 783 N.
Conclusions
Portable fixed dynamometry may significantly reduce examiner-induced ceiling effects, optimize the standardization of muscle strength testing, and maximize reliability. Ultimately, PFD may improve the delivery of care due to its potential for unsupervised, home-based assessments and reduce the burden to the patient of participating in clinical trials for MND or other neuromuscular diseases.
Publisher
Springer Science and Business Media LLC
Subject
Clinical Neurology,Neurology
Reference49 articles.
1. National institute for health and care excellence: clinical guidelines; motor neurone disease: assessment and management (2016). In. national institute for health and care excellence: clinical guidelines. The National Institute of Health and Care Excellence (NICE), London. https://www.nice.org.uk/guidance/ng42
2. Cudkowicz M, Qureshi M, Shefner J (2004) Measures and markers in amyotrophic lateral sclerosis. NeuroRx 1(2):273–283. https://doi.org/10.1602/neurorx.1.2.273
3. Paganoni S, Cudkowicz M, Berry JD (2014) Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig (Lond) 4(7):605–618
4. Rutkove SB (2015) Clinical measures of disease progression in amyotrophic lateral sclerosis. Neurotherapeutics 12(2):384–393. https://doi.org/10.1007/s13311-014-0331-9
5. Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, Hayden D, Shui A, Brooks B, Conwit R, Felsenstein D, Greenblatt DJ, Keroack M, Kissel JT, Miller R, Rosenfeld J, Rothstein JD, Simpson E, Tolkoff-Rubin N, Zinman L, Shefner JM, Ceftriaxone Study I (2014) Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol 13(11):1083–1091. https://doi.org/10.1016/S1474-4422(14)70222-4
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献